Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax and/or Navitoclax with Chemotherapy in T-ALL/T-LBL
NCT06210750Phase 2Withdrawn
- Sponsor
- National Cancer Institute
- Start
- Aug 2024
- Primary completion
- Sep 2026
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of venetoclax, navitoclax in acute lymphoblastic leukemia (ALL), T-cell lymphoblastic lymphoma (T-LBL), sponsored by National Cancer Institute. Planned start Aug 2024; status: withdrawn.
02
Drugs
venetoclaxnavitoclax
03
Conditions
acute lymphoblastic leukemia (ALL)T-cell lymphoblastic lymphoma (T-LBL)
Beyond the preview
Go deeper on NCT06210750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06210750.